Genkyotex has built a diverse pipeline of NOX inhibitors. Preclinical studies show that NOX1&4 inhibitors have broad potential across fibrotic and inflammatory diseases of the liver, kidney, lungs and skin.

In addition to NOX1&4 inhibitors, Genkyotex has earlier-stage programs for other indications based on inhibition of different NOX isoforms. The company continues to apply its unique screening platform to further discover new NOX inhibitors with different profiles to address diseases where there is high unmet need.

pipeline of nox inhibitors june 2019 7532b